Somapacitan + Norditropin®
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Growth Hormone Deficiency in Children
Conditions
Growth Hormone Deficiency in Children
Trial Timeline
May 20, 2019 → Sep 30, 2025
NCT ID
NCT03811535About Somapacitan + Norditropin®
Somapacitan + Norditropin® is a phase 3 stage product being developed by Novo Nordisk for Growth Hormone Deficiency in Children. The current trial status is completed. This product is registered under clinical trial identifier NCT03811535. Target conditions include Growth Hormone Deficiency in Children.
What happened to similar drugs?
11 of 20 similar drugs in Growth Hormone Deficiency in Children were approved
Approved (11) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05330325 | Phase 3 | Active |
| NCT04970654 | Phase 3 | Completed |
| NCT03878446 | Phase 2 | Active |
| NCT03811535 | Phase 3 | Completed |
Competing Products
20 competing products in Growth Hormone Deficiency in Children